Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS-Reference-Cited by-同舟云学术

Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS

Published:2021-05-27 Issue:8 Volume:35 Page:1678-1685
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Gutzmer R.¹,Schulze H.‐J.²,Hauschild A.³^ORCID,Leiter U.⁴^ORCID,Meier F.⁵⁶^ORCID,Haferkamp S.⁷,Ulrich C.⁸,Wahl R.U.⁹,Berking C.¹⁰^ORCID,Herbst R.¹¹,Häckl M.¹²,Schadendorf D.¹³¹⁴^ORCID

Affiliation:

1. Klinik für Dermatologie, Mühlenkreiskliniken Minden, Akademisches der Universität Bochum Minden Germany

2. Hauttumorzentrum Hornheide‐Münster Münster Germany

3. Klinik für Dermatologie UKSH Campus Kiel Kiel Germany

4. Zentrum für Dermatoonkologie Universitätsklinikum Tübingen Tübingen Germany

5. Hautkrebszentrum am Universitäts‐Krebscentrum Dresden und Nationales Centrum für Tumorerkrankungen Dresden Germany

6. Abteilung für Dermatologie Universitätsklinikum Carl Gustav Carus, TU Dresden Dresden Germany

7. Klinik und Poliklinik für Dermatologie Universitätsklinikum Regensburg Regensburg Germany

8. Klinik für Dermatologie, Venerologie u. Allergologie Charité Universitätsmedizin Berlin Berlin Germany

9. Klinik für Dermatologie und Allergologie Universitätsklinikum der RWTH Aachen Aachen Germany

10. Hautklinik, Universitätsklinikum ErlangenFriedrich‐Alexander University Erlangen‐Nürnberg (FAU)CCC Erlangen EMN Erlangen Germany

11. Hauttumorzentrum Erfurt Germany

12. Roche Pharma AG Grenzach‐Wyhlen Germany

13. Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie Universitätsklinikum Essen Essen Germany

14. German Cancer Consortium (DKTK), Partner Site Essen Germany

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.17332

Reference25 articles.

1. A systematic review of worldwide incidence of nonmelanoma skin cancer

2. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations

3. Non-Melanoma Skin Cancer Incidence and Impact of Skin Cancer Screening on Incidence

4. New Concepts for Basal Cell Carcinoma. Demographic, Clinical, Histological Risk Factors, and Biomarkers. A Systematic Review of Evidence Regarding Risk for Tumor Development, Susceptibility for Second Primary and Recurrence

5. Metastatic basal cell carcinoma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Advances in Advanced Basal Cell Carcinoma;Cancers;2024-09-04

2. Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options;Biomedicines;2024-06-28

3. Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies;American Journal of Clinical Dermatology;2024-06-19

4. Response to “Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis”;Future Oncology;2023-11-15

5. Response to letter to editor on the article: Ge W, Chen C-I, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol. 18(23), 2561–2572 (2022);Future Oncology;2023-11-14